FDA Approves SGLT2 Inhibitor Ertugliflozin for Type 2 Diabetes FDA Approves SGLT2 Inhibitor Ertugliflozin for Type 2 Diabetes

The US Food and Drug Administration has approved ertugliflozin, a fourth SGLT2 inhibitor for use in adults with type 2 diabetes .Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news